Kirkpatrick Lynn 4
4 · Ensysce Biosciences, Inc. · Filed May 27, 2022
Insider Transaction Report
Form 4
Kirkpatrick Lynn
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2022-05-26$0.53/sh+27,000$14,216→ 381,851 total - Award
Stock Option
2022-02-17+200,000→ 2,516,939 totalExercise: $1.40Exp: 2032-02-17→ Common Stock (200,000 underlying) - Purchase
Common Stock
2022-05-25$0.49/sh+70,000$34,083→ 354,851 total
Footnotes (1)
- [F1]On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.